A formulation manufacturing facility of Aurobindo Pharma subsidiary Eugia Pharma Specialities in Rajasthan has been issued seven observations by the U.S. Food and Drug Administration.
The U.S. FDA had inspected Unit-II, a formulation manufacturing facility, of wholly owned subsidiary Eugia Pharma Specialities in Bhiwadi, Alwar, from April 25 to May 3.
The inspection closed with seven observations. The observations are procedural in nature and will probably be responded to throughout the stipulated time, Aurobindo Pharma stated in a submitting on Friday.
